Advanced Technologies for Novel Therapeutics
Newark
About Advanced Technologies for Novel Therapeutics
TNT founders are well-recognized university professors whose areas of expertise encompass molecular biology, cell biology, biochemistry, molecular genetics, human genetics, animal models, systems biology and engineering disciplines. Their staff members are high profile experts in engineering and biology. In ATNT they have successfully developed novel tools and techniques, to identify the most important therapeutic targets in complex cellular networks. Using patented technologies, ATNT provides a unique service to pharmaceutical and biotech companies. Their service will provide a set of therapeutic targets that have the minimal chance of failure, therefore minimizes the time and cost of finding novel therapeutics.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Estimated revenue: $1K – $10K
- Total funding: $150.0K
- Last round: Grant (Dec 2012)
- Website: atnt-usa.com
- Phone: 9733792546
Industries & Categories
Biotechnology, Life Science
Social Profiles
Canonical: https://fsome.com/organization/advanced-technologies-for-novel-therapeutics-3373945 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.